TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20101012
Drug: Once-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly resistance training (n = 54)
Study: 20101012
Drug: Twice-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly resistance training (n = 52)
Study: 20101012
Drug: Twice-weekly balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly balance and tone training (control group, n = 49)
Study: 12828584
Drug: Aminophylline treatment
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline treatment in group C (n=5)
Study: 10731502
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (30 mg/d for 28 days)
Study: 7506169
Drug: Nimesulide (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100mg orally, twice daily)
Study: 7506169
Drug: Piroxicam (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20mg orally, once daily)
Study: 7506169
Drug: Ketoprofen (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100mg orally, twice daily)
Study: 24238032
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 0.2 mg·kg(‐1)
Study: 24238032
Drug: Promethazine 0.5
Normalized name: PROMETHAZINE 0.5MG/ML/NACL INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 0.5 mg·kg(‐1)
Study: 20007307
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (58 mmol . L(‐1) . d(‐1))
Study: 20007307
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (170 mmol . L(‐1) . d(‐1))
Study: 20007307
Drug: Urinary aldosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary aldosterone excretion rates
Study: 14644671
Drug: Intensive peer
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive peer education sessions (20 bi-weekly sessions over 1 year and quarterly booster sessions for 2 years)
Study: 9690722
Drug: ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 75 mg
Study: 26789727
Drug: NPM1-mutated transcripts
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPM1-mutated transcripts present after second chemotherapy cycle
Study: 26789727
Drug: Sequential monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monitoring of minimal residual disease
Study: 22913215
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of L-arginine for 3 months
Study: 12148095
Drug: Intravenous CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CT angiography (CTA)
Study: 8593974
Drug: Triflusal 300
Normalized name: triflusal 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 300 mg twice daily
Study: 25300507
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy (vPDT)
Study: 20529984
Drug: Small-dose nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose nefopam (50 ng/mL)
Study: 20529984
Drug: Large-dose nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose nefopam (100 ng/mL)
Study: 18824706
Drug: IROX (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IROX (irinotecan 200 mg/m² plus oxaliplatin 85 mg/m²)
Study: 18824706
Drug: Irinotecan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan alone (350 mg/m²)
Study: 9459088
Drug: Purified FSH
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified FSH preparation (9 patients, 35 follicular fluid samples)
Study: 9459088
Drug: FSH-dominant human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FSH-dominant human menopausal gonadotropin (hMG) preparation (9 patients, 34 samples)
Study: 8182402
Drug: Anticoagulant (AC)
Normalized name: CPDA-1 Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant (AC) therapy with intravenous heparin infusion for at least 6 days and oral AC therapy for 3 months
Study: 8182402
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant (non-AC) therapy
Study: 8182402
Drug: Anticoagulant (AC)
Normalized name: CPDA-1 Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant (AC) therapy
Study: 3234438
Drug: Low fat/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat/high malto‐dextrin formula (2.6 g fat/100 ml, 8.1 g carbohydrate/100 ml, 2.8 g malto‐dextrin/100 ml)
Study: 3234438
Drug: High fat/low
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat/low malto‐dextrin formula (3.6 g fat/100 ml, 7.3 g carbohydrate/100 ml, 1.9 g malto‐dextrin/100 ml)
Study: 29153485
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300U/mL (Gla‐300) at 0.4U/kg/day
Study: 29153485
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300U/mL (Gla‐300) at 0.6U/kg/day
Study: 29153485
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100U/mL (Deg‐100) at 0.4U/kg/day
Study: 29153485
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100U/mL (Deg‐100) at 0.6U/kg/day
Study: 22676626
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal conjugate vaccine
Study: 20096138
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 to 40 mg) plus B12 (0.5 mg), B6 (25 mg) and folic acid (2 mg)
Study: 20096138
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 to 40 mg) plus placebo
Study: 19008063
Drug: Dual flow
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual flow injection protocol with saline chaser containing 20% contrast media
Study: 16607927
Drug: Fasting and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting and 2-hour insulin levels
Study: 12580984
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg day(-1)
Study: 7682266
Drug: Aprotinin 20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 20,000 U/kg after induction, 20,000 U/kg added to the prime, and 20,000 U/kg every hour during cardiopulmonary bypass (low-dose regimen)
Study: 7682266
Drug: Aprotinin 35,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 35,000 U/kg after induction followed by an infusion of 10,000 U/kg.min until the end of the operation and 35,000 U/kg added to the prime (high-dose regimen)
Study: 7682266
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (low-dose aprotinin)
Study: 24606088
Drug: Weekly iv
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly iv methylprednisolone
Study: 24606088
Drug: Daily iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iv methylprednisolone
Study: 20683501
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (25-150 mg equivalents)
Study: 20683501
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (25-100 mg equivalents)
Study: 18778865
Drug: Metformin (1000-2000mg/day)
Normalized name: metformin hydrochloride 1000 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (1000-2000mg/day)
Study: 15754408
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection with postoperative chemotherapy
Study: 12066723
Drug: GIK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK group (500 ml of 50% dextrose solution containing 100 IU insulin and potassium 80 mmol infused at 0.75 ml kg(‐1) h(‐1))
Study: 12066723
Drug: Non-GIK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-GIK group (5% dextrose solution infused at the same rate)
Study: 8808179
Drug: Mefloquine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine alone (750 mg)
Study: 8808179
Drug: Mefloquine in
Normalized name: Product containing mefloquine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine in combination with artemether (300 mg, given 24 hours prior)
Study: 18788990
Drug: Isoflavones (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (70 mg) for 6 months
Study: 10810399
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively (Group A)
Study: 10810399
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively plus UFT orally at a dose of 400 mg daily for one year (Group B)
Study: 8857073
Drug: FK613 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK613 5 mg
Study: 8857073
Drug: FK613 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK613 20 mg
Study: 8857073
Drug: FK613 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK613 40 mg twice daily for 6.5 days
Study: 8857073
Drug: FK613 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK613 30 mg or more
Study: 8857073
Drug: Hydrogel-type formulation
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel-type formulation of FK613
Study: 25637937
Drug: Olmesartan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan with ACE inhibitors and β-blockers
Study: 25637937
Drug: Control with
Normalized name: Azo Bladder Control With Go Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control with ACE inhibitors and β-blockers
Study: 21843836
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard doses of oral corticosteroids and physiotherapy limited to airway clearance techniques and breathing exercises)
Study: 17604664
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 microg twice daily
Study: 17604664
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 330 microg twice daily
Study: 17315803
Drug: Prompt L-Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L-Pop + F2000
Study: 8808724
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg i.v. bolus of ondansetron
Study: 8808724
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg i.v. granisetron
Study: 8808724
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg i.v. tropisetron
Study: 8808724
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further antiemetic therapy)
Study: 3936091
Drug: Caffeine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (0 mg/kg) + Diazepam (0.15 mg/kg)
Study: 3936091
Drug: Caffeine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (0 mg/kg) + Diazepam (0.30 mg/kg)
Study: 3936091
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg) + Diazepam (0.15 mg/kg)
Study: 3936091
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg) + Diazepam (0.30 mg/kg)
Study: 3936091
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg) + Diazepam (0.15 mg/kg)
Study: 3936091
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg) + Diazepam (0.30 mg/kg)
Study: 28815560
Drug: Lindioil ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindioil ointment containing 200 μg g‐1 of indirubin
Study: 28815560
Drug: Lindioil ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindioil ointment containing 100 μg g‐1 of indirubin
Study: 28815560
Drug: Lindioil ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindioil ointment containing 50 μg g‐1 of indirubin
Study: 28815560
Drug: Lindioil ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindioil ointment containing 10 μg g‐1 of indirubin
Study: 24140226
Drug: Antidepressants (MED)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (MED)
Study: 24140226
Drug: Combined CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CBT and antidepressants (COMB)
Study: 22648221
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (novel anti-acne/anti-aging formulation)
Study: 22648221
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (tretinoin cream 0.025%)
Study: 18666803
Drug: Irbesartan therapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan therapy for 9 weeks
Study: 18666803
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy for 9 weeks
Study: 16613662
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate 200 mg/m2 daily for 5 days
Study: 16613662
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg (increased to 90 mg for initial serum calcium > or = 13.5 mg/dL) followed by placebo infusions for 4 days
Study: 16613662
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg for initial serum calcium > or = 13.5 mg/dL
Study: 16613662
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg for initial serum calcium > or = 13.5 mg/dL
Study: 16613662
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate for initial serum calcium > or = 13.5 mg/dL
Study: 14616318
Drug: Mivacurium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.1 mg kg‐1 bolus followed by continuous infusion)
Study: 11018164
Drug: long-long regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: long-long regimen (zidovudine starting at 28 weeks' gestation, 6 weeks treatment in infant)
Study: 11018164
Drug: long-short regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: long-short regimen (zidovudine starting at 28 weeks' gestation, 3 days treatment in infant)
Study: 11018164
Drug: short-long regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: short-long regimen (zidovudine starting at 35 weeks' gestation, 6 weeks treatment in infant)
Study: 11018164
Drug: short-short regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: short-short regimen (zidovudine starting at 35 weeks' gestation, 3 days treatment in infant)
Study: 10148407
Drug: Rotorest Kinetic
Normalized name: Kineticream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotorest Kinetic Treatment Table
Study: 6660456
Drug: Lateral position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral position after bupivacaine administration
Study: 6660456
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position after bupivacaine administration
Study: 29998882
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) for 12 weeks followed by Peg-IFN for 48 weeks (sequential treatment)
Study: 27154394
Drug: Enterovirus quantity
Normalized name: human enterovirus A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterovirus quantity at the time of OPV administration
Study: 20102858
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (family-centered program with 12 sessions of behavioral curriculum, dietary advice from a registered dietitian weekly for the first 3 months and monthly thereafter, and monthly consultations with a primary care physician)
Study: 20102858
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly consultations with a primary care physician who received brief training on obesity)
Study: 16787761
Drug: 1% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diclofenac gel
Study: 16787761
Drug: Diclofenac tablets
Normalized name: diclofenac Oral Tablet
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac tablets
Study: 16787761
Drug: Paracetamol tablets
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol tablets
Study: 7478700
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral tramadol
Study: 12386639
Drug: Methylprednisolone alone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone alone (0.3 mg/kg)
Study: 12386639
Drug: Diltiazem alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem alone (180 mg)
Study: 12386639
Drug: Methylprednisolone-diltiazem combination
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone-diltiazem combination
Study: 7845114
Drug: Pulsed intrope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed intrope therapy (PIT) with dobutamine, infused to raise heart rate to 70-80% maximum for 30 min per day, 4 days per week for 3 weeks
Study: 7845114
Drug: Pulsed intrope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed intrope therapy (PIT) with dobutamine
Study: 44632
Drug: Flunitrazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (2 mg on the night before operation followed by 2 mg on the morning of operation)
Study: 23506216
Drug: NeuroAiD (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroAiD (four capsules three times daily for three months)
Study: 23506216
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four capsules three times daily for three months)
Study: 17846459
Drug: Feedback on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback on daily step counts (monitoring and recording step counts during week 1)
Study: 15025611
Drug: 27-G (0.41
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27-G (0.41 mm) Quincke spinal needle
Study: 15025611
Drug: 27-G (0.41
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27-G (0.41 mm) Whitacre spinal needle
Study: 22147094
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4)
Study: 24161160
Drug: Rilpivirine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine (25 mg once daily)
Study: 16766777
Drug: NoExGlc -
Approvals — FDA: no, EMA: no, PMDA: no
Description: NoExGlc - Subjects consumed a 50 g glucose (glc) drink as the reference CHO for GI and insulinemic index (II) determination
Study: 9154401
Drug: terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine (250 mg daily)
Study: 8097683
Drug: Metoprolol (10‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (10‐15 mg plus 150 micrograms min‐1 kg‐1)
Study: 30498827
Drug: High-protein dairy-based
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein dairy-based products and energy-enriched berry purées for three months, providing nearly 300 kcal and 14 g protein per day.
Study: 20956208
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g TID for 2 weeks)
Study: 18761644
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.4 U/kg) in children (8-12 years)
Study: 18761644
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.4 U/kg) in adolescents (13-17 years)
Study: 18761644
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.4 U/kg)
Study: 15850630
Drug: Supervised intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised intake of artemether-lumefantrine (all doses observed with fatty-food intake; n=313)
Study: 15850630
Drug: Unsupervised intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised intake of artemether-lumefantrine (first dose supervised followed by outpatient treatment with nutritional advice; n=644)
Study: 12452220
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine + intravenous ketorolac
Study: 12452220
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac alone
Study: 10777467
Drug: Platinum-based combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based combination chemotherapy administered sequentially or concurrently with thoracic radiation therapy
Study: 10777467
Drug: Thoracic radiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiation therapy combined with novel drugs or new drug combinations